Literature DB >> 3354766

Toxoplasmosis in Panama: a 10-year study.

O E Sousa1, R E Saenz, J K Frenkel.   

Abstract

We studied the prevalence of Toxoplasma antibody over a 10-year period in a rural population of 326 people in Chorrera Province of Panama using the dye test. Fifty-five seroconversions were found in 108 people at risk, and 48 (87%) in children between 2 and 13 years with a mean incidence rate of 8.6% per year. Antibody prevalence rose from 25% at 5 years to 50% at 10 years of age, and increased gradually, reaching 90% by 60 years. Mean antibody levels after seroconversion were 1:6,000 in the dye test; they fell to 1:1,000 after 1 year, 1:800 after 2 years, 1:200 after 3 years, and 1:333 after 7-9 years. About 10% of antibody titers ranged between 1:4 and 1:32. Toxoplasma antibody prevalence was also studied in the metropolitan Panama City population using 590 sera collected in the fall of 1981. Age-specific incidence rates were similar in the urban and rural setting (correlation coefficient 0.71). The number of cats observed in the rural area and in the city and the degree of soil contact appeared compatible with a hypothesis of transmission by oocysts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3354766     DOI: 10.4269/ajtmh.1988.38.315

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

1.  Seroprevalence of human Toxoplasma gondii infection among pregnant women in Charsadda, KP, Pakistan.

Authors:  Shah Faisal; Hasnain Jan; Muhammad Haroon; Muhammad Taimur Khan; Farman Ullah Jan; Tanveer Iqbal; Ayyaz Khan; Muhammad Shakeel
Journal:  J Parasit Dis       Date:  2018-10-15

2.  Direct agglutination test and other assays for measuring antibodies to Toxoplasma gondii.

Authors:  J Johnson; K Duffy; L New; R E Holliman; B S Chessum; D G Fleck
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

3.  Discrepant toxoplasma latex agglutination test results.

Authors:  R E Holliman; J Johnson; K Duffy; L New
Journal:  J Clin Pathol       Date:  1989-02       Impact factor: 3.411

4.  A sero-survey of toxoplasmosis in farm and non-farm children from Wisconsin, United States, 1997-1999.

Authors:  Claudia Muñoz-Zanzi; Jessica Williams-Nguyen; Edward A Belongia
Journal:  BMC Public Health       Date:  2013-09-11       Impact factor: 3.295

5.  Evaluation of the level of awareness of congenital toxoplasmosis and associated practices among pregnant women and health workers in Tanzania's Temeke district in Dar es Salaam.

Authors:  Onduru Gervas Onduru; Susan Fred Rumisha; Musso Munyeme; Andrew Malata Phiri
Journal:  Afr Health Sci       Date:  2019-12       Impact factor: 0.927

6.  Seroepidemiology of human Toxoplasma gondii infection in China.

Authors:  Yue Xiao; Jigang Yin; Ning Jiang; Mei Xiang; Lili Hao; Huijun Lu; Hong Sang; Xianying Liu; Huiji Xu; Johan Ankarklev; Johan Lindh; Qijun Chen
Journal:  BMC Infect Dis       Date:  2010-01-07       Impact factor: 3.090

Review 7.  Toxoplasma gondii: A possible etiologic agent for Alzheimer's disease.

Authors:  Tooran Nayeri; Shahabeddin Sarvi; Mehdi Sharif; Ahmad Daryani
Journal:  Heliyon       Date:  2021-06-03

8.  Seroprevalence and risk factors for Toxoplasmosis in HIV infected and non-infected individuals in Bahir Dar, Northwest Ethiopia.

Authors:  Fisseha Walle; Nigatu Kebede; Aster Tsegaye; Tesfu Kassa
Journal:  Parasit Vectors       Date:  2013-01-16       Impact factor: 3.876

9.  Computational analysis and experimental validation of gene predictions in Toxoplasma gondii.

Authors:  Joseph M Dybas; Carlos J Madrid-Aliste; Fa-Yun Che; Edward Nieves; Dmitry Rykunov; Ruth Hogue Angeletti; Louis M Weiss; Kami Kim; Andras Fiser
Journal:  PLoS One       Date:  2008-12-09       Impact factor: 3.240

10.  EPIC-DB: a proteomics database for studying Apicomplexan organisms.

Authors:  Carlos J Madrid-Aliste; Joseph M Dybas; Ruth Hogue Angeletti; Louis M Weiss; Kami Kim; Istvan Simon; Andras Fiser
Journal:  BMC Genomics       Date:  2009-01-21       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.